Results 171 to 180 of about 494,085 (317)

Use of Systemic Glucocorticoids and Risk of Prostate Adenocarcinoma: Evidence From a Danish Population‐Based Case–Control Study

Cancer Medicine, Volume 14, Issue 15, August 2025.
Use of systemic glucocorticoids and risk of prostate adenocarcinoma: Evidence from a Danish population‐based case–control study. ABSTRACT Background Glucocorticoids may promote prostate cancer by reducing apoptosis and the immune response, or prevent it by reducing inflammation, inhibiting androgens, and limiting cell proliferation.
Elea Olivier, Blánaid Hicks, Morten Olesen, Agnès Fournier, Gianluca Severi, Anton Pottegård, Manon Cairat   +6 more
wiley   +1 more source

Impact of Delay of Treatment With Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. [PDF]

ACR Open Rheumatol
Mease PJ, Nowak M, Choi J, Lehman T, Sreih A, Ho K, Middaugh N, Ogdie A.   +7 more
europepmc   +1 more source

Stress fracture in long term methotrexate treatment for psoriatic arthritis [PDF]

, 2001
Math J. Wijnands, A. C. J. Burgers
openalex   +1 more source

Model‐Informed Drug Development‐Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial Spondyloarthritis

Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 480-488, August 2025.
The objective of this modeling and simulation analysis was to determine an intravenous (IV) secukinumab dosing regimen with steady‐state exposure within the ranges of the approved subcutaneous (SC) regimens (300 and 150 mg every 4 weeks [q4w]) and to predict the efficacy and safety of this IV regimen for patients with psoriatic arthritis (PsA) or axial
Thomas Dumortier, Guillermo Valenzuela, Melvin Churchill, Jelena Mijatovic, Gerard Bruin, Luminita Pricop, Hanno Richards, Didier Renard, Atul Singhal, Anshu Marathe   +9 more
wiley   +1 more source

Molecular imaging of psoriatic arthritis. [PDF]

Curr Opin Rheumatol
Groothuizen S, van der Laken CJ.
europepmc   +1 more source

A TNF-α Promoter Polymorphism Is Associated with Juvenile Onset Psoriasis and Psoriatic Arthritis

, 1997
Thomas Höhler, Anke Krüger, Peter M. Schneider, R.E. Schopf, Jürgen Knop, Christian Rittner, Karl‐H. Meyer zum Büschenfelde, E. Märker‐Hermann   +7 more
openalex   +1 more source

Release of cartilage and bone macromolecules into synovial fluid: differences between psoriatic arthritis and rheumatoid arthritis [PDF]

, 2001
Bengt Månsson
openalex   +1 more source

Cytokine blockers in psoriatic arthritis [PDF]

, 2001
Philip J. Mease
openalex   +1 more source

T Cell‐Specific Deficiency of Src Homology 2‐Containing Protein Tyrosine Phosphatase 2 Ameliorates Psoriasis and Colitis by Promoting Treg Differentiation

MedComm, Volume 6, Issue 8, August 2025.
• SHP2 deficiency in T cells could alleviate both psoriasis‐like skin lesion and adoptive transfer colitis. • SHP2 deficiency in T cells promotes the differentiation toward Treg, thus regulating the balance of Th17/Treg. • SHP2 may become a promising common therapeutic target in the treatment of autoimmune diseases.
Shuqiong Zhang, Zijun Ouyang, Zhidan Fan, Haiyan Sun, Haiguo Yu, Xingxin Wu, Yang Sun, Fenli Shao   +7 more
wiley   +1 more source

Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study. [PDF]

Rheumatology (Oxford)
López-Medina C, Gorlier C, Orbai AM, Coates LC, Kiltz U, Leung YY, Palominos P, Cañete JD, Cañete JD, Scrivo R, Balanescu A, Dernis E, Meisalu S, Ruyssen-Witrand A, Soubrier M, Aydin SZ, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, Smolen JS, de Wit M, Gossec L.   +24 more
europepmc   +1 more source